Prosecution Insights
Last updated: October 25, 2026

Sungkwang Medical Foundation

Technology area: Biotechnology & Pharmaceuticals

6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Sungkwang Medical Foundation has 5 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 5 distinct examiners and 5 distinct art units, so each pending matter is associated with a separate examination assignment in the available data. This structure favors individualized response planning, particularly where claim scope, technical disclosures, and cited references may differ across matters.

LULTSCHIK, WILLIAM G is the busiest examiner, with 1 pending action. No examiner has a larger concentration in the profile, which limits the value of an examiner-specific portfolio approach. Counsel can instead use a common internal review framework while preserving separate analyses for each art unit and examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

6
Total Pending OAs
2
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (67%)
0
Medium (0%)
2
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other3 (50%)
§112 only2 (33%)
Multi-statute (no §101)1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
33% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LULTSCHIK, WILLIAM G 1 22.5% +31.6%
JANG, CHRISTIAN Y 1 68.7% +21.0%
GRAY, JESSICA 1 0.0% +0.0%
NGUYEN, NGHI V 1 53.6% +50.8%
WILSON, MICHAEL C 1 41.5% +17.8%
REGLAS, GILLIAN CHELSEA 1 32.3% +37.5%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18556783 MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF NGUYEN, NGHI V 28d overdue
19127953 SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME LULTSCHIK, WILLIAM G —
18683683 ANALYSIS METHOD FOR PREECLAMPSIA DIAGNOSIS USING METHYLATION LEVEL IN CPG SITE GRAY, JESSICA —
18264521 METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS WILSON, MICHAEL C —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18556783 MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF NGUYEN, NGHI V 28d overdue
19127953 SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME LULTSCHIK, WILLIAM G —
18846979 METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME JANG, CHRISTIAN Y —
18264521 METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS WILSON, MICHAEL C —
17296137 A COMPOSITION COMPRISING MESENCHYMAL STEM CELLS FOR INHIBITING ADIPOGENESIS REGLAS, GILLIAN CHELSEA —

Top Art Units

Art UnitApps
3682 1
3791 1
1682 1
1653 1
1638 1
1632 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19127953 SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME LULTSCHIK, WILLIAM G 3682 §101§103 Non-Final OA — Pending Aug 29, 2025
18846979 METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME JANG, CHRISTIAN Y 3791 §112 Final Rejection — Pending Sep 13, 2024
18683683 ANALYSIS METHOD FOR PREECLAMPSIA DIAGNOSIS USING METHYLATION LEVEL IN CPG SITE GRAY, JESSICA 1682 §101§102§103§112 Non-Final OA — Pending Feb 14, 2024
18556783 MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF NGUYEN, NGHI V 1653 §101§103 Final Rejection 28d overdue Pending Oct 23, 2023
18264521 METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS WILSON, MICHAEL C 1638 §103§112 Final Rejection — Pending Aug 07, 2023
17296137 A COMPOSITION COMPRISING MESENCHYMAL STEM CELLS FOR INHIBITING ADIPOGENESIS REGLAS, GILLIAN CHELSEA 1632 §112 Final Rejection — Pending May 21, 2021

Managing Sungkwang Medical Foundation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Sungkwang Medical Foundation have?

Sungkwang Medical Foundation has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.

Which USPTO examiner handles the most Sungkwang Medical Foundation applications?

William G Lultschik has the most, with 1 of Sungkwang Medical Foundation's pending office actions.

What technology area are Sungkwang Medical Foundation's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month